Table 1 Incidence of CID and risk of first CID occurrence in total population and by GOLD stage
From: Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Overall population | GOLD 2 | GOLD 3 | GOLD 4 | |
|---|---|---|---|---|
Total UPLIFT population (placebo and tiotropium combined) | ||||
Number of patients, n (%) | 5652 (100.0) | 2603 (100.0) | 2505 (100.0) | 481 (100.0) |
At least one of SGRQ deterioration (decrease of ≥4 units), trough FEV1 decline ≥100 mL or moderate/severe exacerbation | 4741 (83.9) | 2175 (83.6) | 2127 (84.9) | 388 (80.7) |
Moderate/severe exacerbation | 3814 (67.5) | 1615 (62.0) | 1796 (71.7) | 357 (74.2) |
Trough FEV1 decline ≥100 mL | 2503 (44.3) | 1344 (51.6) | 1031 (41.2) | 100 (20.8) |
SGRQ score increase ≥4 units | 2339 (41.4) | 1081 (41.5) | 1054 (42.1) | 178 (37.0) |